US Debate Over Breast Test Coverage

There’s an ongoing national discussion about insurance coverage for a breast cancer biomarker test, specifically related to DCIS—a form of non-invasive breast cancer found in milk ducts. What makes DCIS challenging is its unpredictable nature, and doctors often need more clarity to determine which patients might actually benefit from radiation. The test in question offers a deeper look at tumor biology, aiming to predict both the chance of recurrence and whether radiation would make a difference. Supporters believe this could mean more personalized treatment—helping some women avoid unnecessary radiation and guiding others toward it when beneficial. However, the question remains: do these biomarker tests provide enough additional value over current methods to warrant national insurance coverage? While federal agencies acknowledge the innovation, these lab tests aren’t yet included in the new accelerated coverage pathway. Another advisory panel will meet on October 13 to consider next steps. In my work designing benefit plans, I understand how policy decisions like these can impact both individuals and organizations—especially when it comes to coverage for innovative medical solutions.